Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$5.04 USD
+0.16 (3.28%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $5.04 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Brokerage Reports
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 41 - 60 ( 406 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Assuming at Neutral & $3 PT; On A QUEST to Disrupt the Anaphylaxis Market;
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
AQST-109 End-of-Phase 2 Meeting Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
2023 Outlook - New Commercial Launches, Clinical Catalysts & M&A Driving Value
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
EOP2 Minutes Sets the Stage for Pivotal PK Study for AQST-109 in 2023
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
EoP2 Meeting For AQST-109 in Q4; Libervant Updates; Q3 Financials
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Weekly Symphony Health Estimates for SYMPAZAN
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Positive AQST-109 EPIPHAST II Top-Line Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Topline Results from EPIPHAST II for AQST-109/Anaphylaxis; EoPh2 Meeting in Q4
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Weekly Symphony Health Estimates for SYMPAZAN
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant Receives Tentative FDA Approval; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R